Newsroom


Ultromics Logo
Ultromics granted FDA Breakthrough Device Designation for AI-enhanced Cardiac Amyloidosis detection

| By Ultromics

Oxford, UK, April 26th, 2023 — Ultromics, a leader in the field of artificial intelligence-powered diagnostics for heart failure, has been granted FDA Breakthrough Device Status for its AI-enhanced platform for detecting cardiac amyloidosis.


Research Logo
NEURO-TTRansform Phase III results presented at AAN showed eplontersen demonstrated consistent and sustained improvement in all measures of disease and quality of life through 66 weeks

WILMINGTON, Del.--()--Detailed results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed AstraZeneca and Ionis’ eplontersen met all co-primary endpoints and secondary endpoints at 66 weeks versus an external placebo group.1


Read Now Button
2023 Spring Newsletter
Be sure to catch up on the latest happenings in our spring newsletter.